You can narrow down the results using the filters
-
Safety and efficacy of biodegradable biliary and pancreatic stents
Expand descriptionBiliary or pancreatic stents are used for management of ductal obstruction. Currently, biliary or pancreatic stents are made of either plastic or metal alloy. As a result, repeat endoscopic retrograde cholangio-pancreatography (ERCP) is necessary for stent removal. Our aim is to study the feasibility, safety and technical performance of the novel bio-degradable stent (ARCHIMEDES) in 3 patient groups: (1) Post liver transplant duct to duct anastomotic strictures; (2) hepaticojejunostomy anastomotic strictures and (3) patients requiring post ERCP pancreatitis prophylaxis with pancreatic stent placement.
-
The effectiveness and cost-effectiveness of a web-based intervention to support colorectal cancer patients prepare for and recover from surgery: A randomised controlled trial of the RecoverEsupport intervention.
Expand descriptionThis study is aimed at testing the effectiveness and cost-effectiveness of the RecoverEsupport digital health program in supporting colorectal cancer patients undergoing surgery. Who is it for? You may be eligible for this trial if you are aged 18 years or older, have been diagnosed with colorectal cancer, and are planning to undergo bowel resection with an expected inpatient stay of at least 3 days. Study details Participants who choose to enrol in this study will be randomly allocated by chance (similar to flipping a coin) to either the intervention or a usual care group. Participants allocated to the intervention will be asked to access the RecoverEsupport website to complete online activities, learn about pre- and post-surgery behaviours, and access behaviour change strategies to enhance their recovery. Participants and clinicians will also receive prompts (e.g. SMS or email) to support adherence to Enhanced Recovery After Surgery (ERAS) recommendations. This intervention will occur from 2 weeks before surgery, to 3 months after surgery. Those participants who are randomised into the control group will receive usual care. Questionnaires will be collected at baseline, post-surgery, 1 months and 3 months after surgery. It is hoped this intervention will facilitate improved implementation of ERAS, and improve patients' recovery from surgery.
-
Shoes for self-managing Chronic HIP Pain: the SCHIPP randomised clinical trial
Expand descriptionChronic hip pain is a highly prevalent condition that is largely due to osteoarthritis (OA). Hip OA affects around 40 million people globally and is a leading cause of years lived with disability. With an ageing population and rising rates of obesity, the condition is projected to increase by 58% in Australia over the next decade, leading to substantial societal and health care burden. As hip OA has no cure, advice on self-management of symptoms is recommended as a core treatment component for all patients with hip OA. Currently, footwear guidelines for people with hip OA are based solely on expert opinion, and no research has investigated which type of shoes are most effective at reducing symptoms in people with chronic hip pain. We are conducting a research study to compare two classes of readily available off-the-shelf shoes on individual's self-reported hip pain. To do this, we will allocate people via a random process into two different groups. Participants in each group will be provided with 2 pairs of different shoes to wear daily for 6 months. To ensure that this is a fair and unbiased evaluation, we will not disclose the differences in the shoe classes between the two groups until the end of the study. There will be an equal number of participants in each group, and participants will not be able to choose which group they are in. The findings of this study will help determine which shoes are best for people with chronic hip pain and will guide clinicians in providing appropriate evidence-based footwear advice for their patients. The findings of this study will be published in medical journals and be presented at conferences.
-
The efficacy of Isatuximab plus Pomalidomine and Dexamethasone in patients with amyloid light-chain (AL) amyloidosis who have not responded to previous therapy
Expand descriptionThis study aims to assess the effect of Isatuximab (an immunological treatment) in combination with Pomalidomide and Dexamethasone for the treatment of patients with amyloid light-chain (AL) amyloidosis who have not responded to previous treatments. Who is it for? You may be eligible for this study if you are aged 18 or older, you have been diagnosed with AL amyloidosis and you have not had a successful response to previous targeted treatments. Study details Participants who choose to enrol in this study will all receive 9 to 12 cycles (each cycle is 28 days) of Isatuximab (administered into a vein) and oral Pomalidomide from day 1 to day 21 and oral Dexamethasone weekly on days 1, 8, 15 and 22. For each participant, the treatment period will be 12 months, unless complete response is observed at the completion of 9 cycles, there is disease progression or unacceptable toxicity occurs. Participants will be asked to provide blood and urine samples and other procedures at certain timepoints to assess how they are responding to treatment and to check for any side effects. It is hoped this research will determine whether Isatuximab is effective at treating AL amyloidosis, and determine the maximum number of treatment cycles needed. If Isatuximab is found to be an effective treatment, it may be used to improve the health outcomes of future patients with AL amyloidosis.
-
NHL35: A study of Pembrolizumab And Chemo-Immunotherapy as FIrst-line therapy for patients with primary mediastinal B-Cell lymphoma.
Expand descriptionThis trial is for patients with primary mediastinal B-cell lymphoma (PMBL) and is evaluating if combining pembrolizumab with R-CHOP (Rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) will improve patient outcomes. All patients will receive the following treatment regimen: Cycle 1-2: R-pembro ‘window’ (21-day cycle) * rituximab 375mg/m2 Intravenous Infusion on Day 1 * pembrolizumab 200mg Intravenous Infusion on Day 1 Cycle 3-8: ‘Induction’ (21-day cycle) * rituximab 375mg/m2 Intravenous Infusion on Day 1 * cyclophosphamide 750mg/m2 Intravenous Infusion on Day 1 *doxorubicin 50mg/m2 Intravenous Infusion on Day 1 *vincristine 1.4mg/m2 Intravenous Infusion on Day 1 capped at 2mg *prednisolone 100mg oral tablet on Days 1-5 pembrolizumab 200mg Intravenous Infusion on D1 Cycle 9-17: Pembrolizumab ‘Consolidation’ (21-day cycle) * pembrolizumab 200mg Intravenous Infusion on Day1 Patients will have a PET/CT Scan at the following timepoints 1. After Registration 2. After the "Pembro" phase 3. After the "Induction" phase 4. Patients may have another PET/CT scan at the discretion of their treating physician. Patients will also have blood samples taken every three weeks whilst receiving treatment. It is hoped that this study may demonstrate that addition of pembrolizumab to R-CHOP may improve survival in patients with PMBL.
-
Patient preference and safety of self-removal of ureteric stents
Expand descriptionFollowing treatment of urinary tract stones, ureteric stents are typically left in for one to two weeks post-operatively. Removal of these stents can be performed in multiple ways - either by the patient themselves, by a nurse or via a subsequent procedure. This study investigates these methods of ureteric stent removal to see which is better tolerated by patients. We hypothesise that self-removal of ureteric stents will be preferable. This is because of convenience, reducing risk of potential exposure to COVID-19 and reducing hospital costs.
-
Specialised Dietary Fibre Intervention in Children with Type 1 Diabetes
Expand descriptionThis is a 12-week double-blinded randomized control trial designed to assess the safety, feasibility and tolerability of a specialised resistant starch (dietary fibre) supplement targeting the gut microbiota in children and adolescents with established type 1 diabetes (T1D); and to explore what impact the resistant starch supplement has on short chain fatty acid profiles, gut microbiome signatures, and glycaemic control. Previous research has shown resistant starch (dietary fibre) supplements can be added to the normal diet, modify the gut microbiota and promote release of large amounts of the short chain fatty acids (SCFAs) after fermentation in the colon. In mice, an increase in SCFAs acetate and butyrate stopped pancreatic beta-cell damage providing near-complete protection from T1D. Studies in healthy human adults have shown tapioca-based type 4 resistant starch supplement was well tolerated and improved glycaemic profiles through a reduction in post-prandial glucose and insulin excursions. In this study, children aged 5 – 16 years with T1D for at least 3 months, and no exclusion criteria, will be randomized to the intervention (tapioca-based type 4 resistant starch) or control (maize-based type 2 resistant starch) group. They will take this resistant starch (dietary fibre) supplement daily for six weeks as part of their usual diet then return to their usual diet (without the resistant starch dietary fibre supplement) for the final six weeks. They will be monitored throughout the study via in-person study visits (screening (visit 1, week -2), baseline (visit 2, week 0), end of resistant starch supplementation (visit 3, week 6), end of study (visit 4, week 12)) and phone reviews (weekly phone reviews while on the resistant starch supplement), with various parameters being measured / collected including stool samples, diabetes-related and gastrointestinal symptoms-related quality of life (QoL) questionnaires, supplement tolerability surveys, food diaries, continuous glucose monitoring (CGM) data, insulin dose reviews, and anthropometry. The hypothesis is that addition of a resistant starch (dietary fibre) supplement to the usual diet of children and adolescents with established T1D will be safe, feasible and tolerable; and it will have a positive impact on their glycaemic control; with the tapioca-based type 4 resistant starch supplement being the superior of the two resistant starch supplements with regards to all outcome measures. It is hoped this study will provide important preliminary data for a Phase II study looking at efficacy of this resistant starch supplement for preservation of beta-cell function and improving glucose homeostasis in children with newly diagnosed T1D.
-
Standardised Treatment And Monitoring Protocol to assess safety and tolerability of phage therapy in adults and children (STAMP study)
Expand descriptionA standardised treatment and monitoring protocol for Australian adult and paediatric patients requiring bacteriophage therapy is proposed, with no comparator arm. Patients included are those who have exhausted other therapeutic options for control of their infection and are being treated with phage products according to the special access scheme (SAS) as determined by the Australian Therapeutic Goods Administration (TGA) – so-called “compassionate access”. Patients who are assessed to be suitable for phage therapy will receive this as an adjunct to routine clinical care. The purpose of the study is to standardise therapeutic management and data collection in this setting and to assess overall safety and tolerability of phage therapy, as well as the feasibility of such a standardised national protocol.
-
A feasibility trial of flat, flexible school shoes for management of adolescent patellofemoral pain
Expand descriptionPatellofemoral pain is experienced by one in four adolescents. This pain is debilitating, leads to reduced quality of life and decreased participation in physical activity. Adolescent patellofemoral pain persists into adulthood, with up to 78% continuing to experience pain up to 20 years later. A longer duration of patellofemoral pain is the most consistent predictor of poor prognosis, highlighting the need to intervene early. We know very little about how to effectively manage patellofemoral pain in adolescents. Evidence-based treatments that are effective in adults, such as exercise therapy, are not as effective in adolescent populations. Adolescents spend up to nine hours per weekday in stiff, raised heel school shoes whilst performing a significant amount of their daily physical activity. Stiff, raised heel shoes are known to elevate patellofemoral joint loads. Flat, flexible footwear have been shown to reduce patellofemoral joint loads. This is a simple, low-cost treatment option that directly targets repetitive patellofemoral joint loading known to contribute to pain in adolescents. This trial will determine the feasibility of conducting a full-scale randomised clinical trial investigating flat, flexible school shoes for adolescents with patellofemoral pain. Findings will inform future large-scale clinical trials and guide clinical practice guidelines for management of adolescent patellofemoral pain.
-
Queensland COVID-19 Vaccination (QoVAX) Safety and Efficacy Trial Program: Mixed Dose 1 and 2 Study
Expand descriptionThe overarching primary research question for the QoVax SET Mixed Dose 1 and 2 study is; In the Queensland community, do heterologous COVID-19 vaccine doses 1 and 2 compared with homologous doses 1 and 2, offer higher recall levels of spike IgG, spike IgA, neutralizing IgG, and cell mediated immunity at 4 months post dose 2. The QoVAX Mixed Dose 1 and 2 study will address these specific research questions; 1. What are the host intrinsic (HLA type, genetic traits, immunological T and B cell receptor repertoires) and extrinsic factors (socio-economic health determinants, environmental exposures e.g. smoking) associated with variation in immune outcomes following vaccination? 2. Do members of the community who identify as Aboriginal and/or Torres Strait and/or South Sea Islander, or as being from diverse ethnic backgrounds, show similar vaccine responses? 3. Do certain pre-existing health conditions (autoimmunity, cancer, immunodeficiency), and medication use effect response variation of primary immune outcome measures? Further research objectives are to investigate medium-term health outcomes of vaccinated research participants at 12 months following recruitment, to identify factors associated with i) safety outcomes, and ii) vaccine efficacy outcomes in the study cohort.